By Dr. Ari WeitznerSome have speculated that the anti-VEGF injections we give to macular degeneration patients may get into the bloodstream and have adverse vascular effects. According to a recently released retrospective study (appearing in the October 2010 issue of the Archives of Ophthalmology), using vascular endothelial growth factor (VEGF) blockers to treat neovascular age-related […]